CDC’s Walensky to Review Agency After Covid Response Outcry
(Bloomberg) -- The U.S. Centers for Disease Control and Prevention plans to conduct a review after facing a wave of criticism for its response to the Covid-19 pandemic.
In an agency-wide message to her leadership team and staff on Monday, CDC Director Rochelle Walensky shared her plans to review the agency's structure, saying that “never in its 75 years history has CDC had to make decisions so quickly, based on often limited, real-time, and evolving science.” She said an external senior federal health official was hired for an evaluation of CDC's structure, systems and processes, according to an earlier report published by the Washington Post.
The agency has come under strain and scrutiny as it was forced to quickly take action during the pandemic based on data developed at top speed. The barbs have come in from all sides, as both Democrats and Republicans have questioned the agency's advice and actions.
“What really the pandemic has revealed to us is that our entire public health system is in need of modernization and some support,” said Julie Gerberding, who led the agency from 2002 to 2009, in an online discussion of five former CDC directors held by the Harvard T.H. Chan School of Public Health. Gerberding now serves as drugmaker Merck & Co.'s chief patient officer.
The agency has repeatedly been criticized for Covid guidelines involving health workers, such as earlier this year when it shortened recommended periods for isolation and quarantine. After that, it came under fire for not backing routine testing for exposed people before resuming normal activities.
Shortening those periods was intended to get exposed people back to work faster and help reduce staffing shortages. Still, some labor groups and public-health experts said the guidance prioritized the needs of businesses, supply chains and schools over those of vulnerable workers.
‘Very Healthy'
Asking for help from outside the agency is “very healthy,” said Bill Foege, a physician and epidemiologist who led the CDC from 1977 to 1983. He said he's been pushing for the National Academies of Sciences, Engineering and Medicine to review the CDC.
“I don't know if this is going to be enough,” he said at the Harvard forum. “There are a number of things that should be looked at.”
Last month, Democratic Representative Ro Khanna of California sent a letter to Walensky warning that confusing Covid-19 prevention guidelines should be clarified for hospitals and clinics. The newest guidance also puts front-line workers at risk, he said.
The CDC also plans to take back its role as the main agency collecting hospital data on infectious disease threats. It was stripped of the role mid-pandemic because of its slow response.
Under a new proposal, hospitals participating in the U.S. Medicare and Medicaid programs would be required to funnel hospital data to the CDC's infection-tracking service.
“As we've challenged our state and local partners, we know that now is the time for CDC to integrate the lessons learned into a strategy for the future,” Walensky said in a section of the letter seen by Bloomberg News.
©2022 Bloomberg L.P.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.